The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
 
Michael S Binkley
No Relationships to Disclose
 
Young-Jun Jeon
No Relationships to Disclose
 
Monica Nesselbush
No Relationships to Disclose
 
Everett J Moding
No Relationships to Disclose
 
Barzin Nabet
Patents, Royalties, Other Intellectual Property - I have a patent pending related to immunomodulatory nucleic acids. (Inst)
 
Diego S Almanza
No Relationships to Disclose
 
Christopher Yoo
No Relationships to Disclose
 
David Matthew Kurtz
Consulting or Advisory Role - Roche Molecular Diagnostics
 
Susie Grant Owen
No Relationships to Disclose
 
Leah Monique Backhus
Employment - Department of Veteran Affairs; Stanford University
Leadership - ACGME; Patient-Centered Outcomes Research Institute (PCORI)
Other Relationship - Patient-Centered Outcomes Research Institute (PCORI)
 
Mark F. Berry
No Relationships to Disclose
 
Joseph B Shrager
Consulting or Advisory Role - Becton Dickinson
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - 2 Patents - a potential pharmacological means of preventing ventilator-induced diaphragm dysfunction -a potential use of CRISPR for EGFR mutant lung cancer therapy
 
Kavitha Ramchandran
Consulting or Advisory Role - Drishti
 
Sukhmani Kaur Padda
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; Pfizer
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); EpicentRx (Inst); Forty Seven (Inst)
 
Millie Das
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Research Funding - Abbvie; Celgene; United Therapeutics; Varian Medical Systems; Verily
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; CME Matters; Medscape; MJH Life Sciences; MLI Peerview; Prime Oncology; Research to Practice; Rockpointe
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Takeda
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Heather A. Wakelee
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Helsinn Therapeutics; Janssen Oncology; Mirati Therapeutics; Xcovery
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck; Takeda
 
Ash A. Alizadeh
Leadership - Lymphoma Research Foundation
Stock and Other Ownership Interests - CAPP Medical; CiberMed; Forty Seven
Honoraria - Janssen Oncology; Janssen Oncology; Roche
Consulting or Advisory Role - Celgene; Gilead Sciences; Roche/Genentech
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection, assigned to Stanford University. (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Roche
 
Billy W. Loo
Leadership - TibaRay, Inc.
Research Funding - Varian Medical Systems
 
Maximilian Diehn
Stock and Other Ownership Interests - CiberMed
Consulting or Advisory Role - AstraZeneca; BioNTech; Roche
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection assigned to Stanford University (Inst); Patent filings on tumor treatment resistance mechanisms assigned to Stanford University (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Varian Medical Systems